Study Identifies Genetic Marker Helpful in Guiding Brain Tumor Treatment
Researchers at the University of Kentucky have identified a key genetic biomarker that treatment teams could rely on to predict which patients having glioblastoma stand higher chances of benefiting from bevacizumab, a cancer drug. The study, whose findings were published in the journal JCO Precision Oncology, found that patients who had a genetic alteration referred to as CDK4 and were treated using bevacizumab tended to have longer survival times when compared to patients that underwent the same treatment but didn’t have this genetic change. This finding suggests that conducting tests to identify this particular genetic change could help medical teams…
